Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Transient ischaemic attack? 154 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 154 reports of Transient ischaemic attack have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.1% of all adverse event reports for EVOLOCUMAB.

154
Reports of Transient ischaemic attack with EVOLOCUMAB
0.1%
of all EVOLOCUMAB reports
2
Deaths
71
Hospitalizations

How Dangerous Is Transient ischaemic attack From EVOLOCUMAB?

Of the 154 reports, 2 (1.3%) resulted in death, 71 (46.1%) required hospitalization, and 4 (2.6%) were considered life-threatening.

Is Transient ischaemic attack Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 154 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Transient ischaemic attack?

APIXABAN (1,157) RIVAROXABAN (820) LENALIDOMIDE (655) ADALIMUMAB (604) ASPIRIN (587) ROSIGLITAZONE (585) NAPROXEN (521) LEVOTHYROXINE (517) DABIGATRAN ETEXILATE (471) CLOPIDOGREL BISULFATE (454)

Which EVOLOCUMAB Alternatives Have Lower Transient ischaemic attack Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Transient ischaemic attack Reports All Drugs Causing Transient ischaemic attack EVOLOCUMAB Demographics